Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772405 | 0.85 | PDE4B (0.65) | MAPTSMN1; SMN2KDM4EPDE4BNPC1 | |
| SCHEMBL2626727 | 0.85 | MAPT (0.63) | MAPTSMN1; SMN2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL31133246 | 0.84 | SMN1; SMN2 (0.61) | MAPTSMN1; SMN2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL2457450 | 0.84 | NPC1 (0.61) | MAPTSMN1; SMN2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL2626726 | 0.84 | SMN1; SMN2 (0.61) | MAPTSMN1; SMN2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL9836742 | 0.82 | MAPT (0.51) | MAPTSMN1; SMN2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL6290555 | 0.82 | MAPT (0.69) | MAPTSMN1; SMN2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL2457003 | 0.81 | MAPT (0.67) | MAPTSMN1; SMN2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL9836698 | 0.80 | MAPT (0.49) | MAPTSMN1; SMN2KDM4EALDH1A1PDE4B | |
| SCHEMBL9836753 | 0.79 | PDE4B (0.48) | MAPTSMN1; SMN2KDM4EALDH1A1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003663-B2 | N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003663-B2 | N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090318494-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| EP-1539753-B1 | PYRAZOLO(3,4-B)PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-09-09 | — | — | EP | disclosed |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| WO-2007036733-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| EP-1737857-A1 | PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-01-03 | — | — | EP | disclosed |
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-04-27 | — | — | US | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| EP-1539753-A2 | PYRAZOLO(3,4-B)PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | MAPT 2239/4885SMN1; SMN2 4192/4885KDM4E 378/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | MAPT 4609/4885SMN1; SMN2 3929/4885KDM4E 234/4885 |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | PDE4B, PDE3B, PDE4A | MAPT 4764/4885SMN1; SMN2 4686/4885KDM4E 829/4885 |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | MAPT 3585/4885SMN1; SMN2 3940/4885KDM4E 224/4885 |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | PDE5A, PDE3B, PDE4A | MAPT 4831/4885SMN1; SMN2 4454/4885KDM4E 818/4885 |
| US-20090318494-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | MAPT 4303/4885SMN1; SMN2 3847/4885KDM4E 230/4885 |
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE5A, PDE3B, PDE4A | MAPT 4831/4885SMN1; SMN2 4454/4885KDM4E 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.